We carried out a retrospective study on the prevalence of HPV and genotype distribution by nested PCR and nucleotide sequencing analysis, in formalin-fixed, paraffin-embedded biopsies of 135 head and neck cancers (HNC) and 29 cervical cancers received between 2009 and 2017 for diagnosis at the Laboratoire National de Biologie Clinique et de Santé Publique of Bangui, the capital city of the Central African Republic. One oropharyngeal squamous cell carcinoma sample was positive for HPV type 16. The overall HPV prevalence in HNC biopsies was 0.74% (95% CI: 0.0-2.2). Among the 29 cervical cancer samples, 19 (65.5%; 95% CI: 48.2-82.8) were positive for HPV. These results indicate that HNC are infrequently associated with HPV infection in the Central African Republic.
Head and neck cancers (HNC), excluding nasopharyngeal, most frequently squamous cell carcinoma, are among the most aggressive tumours worldwide [1] . In addition to alcohol and tobacco consumption, human papillomaviruses (HPV) have shown to be associated with the development of a significant proportion of oropharyngeal cancers [2] . Since 2007, HPV is considered as an independent risk factor for head and neck squamous cell carcinoma (HNSCC) by the World Health Organization (WHO)'s International Agency for Research on Cancer (WHO/IARC) [2] . Recently, the "4th Edition of the WHO Classification of Head and Neck Tumours: Oropharynx", classifies the squamous cell carcinoma of the oropharynx (OPSCC) on the basis of HPV status [3] . HPV-positive OPSCC constitutes a tumor entity with a distinct epidemiological profile, with specific genetic features, clinical presentations and outcomes.
Although HPV contribution to HNC is substantial, high heterogeneity by cancer site, region and sex has been reported [4] . Population-based cancer registries have demonstrated a clear pattern of increasing incidence of HPV-related OPSCC in developed countries across multiple continents. However, here is a paucity of knowledge on the role of HPV in HNC in the majority of developing countries, including in Africa [5] . A recent study in West Africa (Senegal) reported a very low prevalence (3.4%) of HPV in HNC biopsies, suggesting no significant association with HPV infection [6] . Similarly, two other studies from Mozambique and Nigeria failed to detect HPV DNA in HNC biopsies [7, 8] .In South Africa, the overall incidence for HNC declined in the general population from 1994 to 2013, but the relationship of HNC and HPV was not investigated [9] . In Middle Africa, the incidence of HNC was estimated nearly two-fold lower than the worldwide rate (4.5 versus 8.0 per 100,000 new cases/year), while an unexpected high incidence of HNC (9.4) was recently reported in Gabon [10] . In the context of high prevalence of oncogenic HPV and HPV-related cervical cancer in Gabon, the possibility of increasing incidence of HPV-related HNC has been hypothesized, but not yet demonstrated [11] .
The aim of our research was to provide original data on the role of HPV in invasive HNC in the Central African Republic, a country of Middle Africa, where cervical cancer is the second most frequent cancer in women between 15 and 44 years of age, suggesting high prevalences of oncogenic HPV among general population [12] . The crude incidence rates of HNC were estimated in 2015 at 1.2 in males and 0.5 in females per 100,000 and per year [8] .
The Laboratoire National de Biologie Clinique et de Santé Publique ("LNBCSP") of Bangui, the capital city of the Central African Republic, is the reference national laboratory in laboratory medicine, including pathology laboratory. The LNBCSP received all biospies and other pathological investigations for the whole country, and also implement the cancer registration.
During 2009 to 2017, the LNBCSP received 135 invasive biopsies from HNC (Table 1) . For each specimen, routine histological examination on hematoxylin-eosin stained slide prepared from a formalin-fixed, paraffin-embedded (FFPE) biopsy, confirmed invasive diagnosis.
Afterwards, a paraffin tissue 5-to 20-μm sections was subjected to virological analysis into the ISO 15189-accredited virology laboratory of the Hôpital européen Georges Pompidou, Paris, France. Indeed, FFPE biopsy samples are frequently the only available ones for molecular testing after pathological examination. However, FFPE samples necessitate specific processing before PCR analysis because formalin fixation induces fragmentation of nucleic acids. Thus, the sample was treated with 250 μl of freshly prepared proteinase K solution to extract and purify DNA onto a silicate column (QIAmp DNA mini kit, Qiagen, Courtaboeuf, France), following manufacturer's instructions. Finally, the total DNA was eluted with 100 μl of DNase-free elution buffer.. The amplification of albumin DNA by in house real-time PCR was used as marker of DNA integrity. Finally, a 1 μg amount of extracted DNA was amplified by "hot start" PCR with degenerate HPV consensus primers MY09 and MY11, as described previously [13] , followed by nested PCR using the GP5+ and GP6+ primers, as previously described [13] .
FFPE biopsies of 25 squamous cell carcinoma and 4 adenocarcinoma of the cervix were also analyzed in parallel. Caskie cells (ATCC® CRM-CRL-1550) were used to obtain HPV DNA-positive control. Each isolate was sequenced in both directions. HPV genotypes were determined by direct sequencing of PCR products. Briefly, amplicons were subjected to cycle sequencing with the ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems Foster City, California, USA). The sequencing reactions were then run on the ABI Prism 3700 Genetic Analyzer (Applied Biosystems). All clinical sequences were submitted to the BLAST server (https://blast.ncbi.nlm.nih.gov/Blast.cgi) to be aligned and One-sided, 97.5% confidence interval CI Confidence interval matched with all HPV sequences available within this database. HPV type was identified on the basis of ≥95% sequence homology in L1 region from HPV sequences available in HPV online databases. The assigned genotype was further confirmed by phylogenetic assay using Mega 2.1 software (www.megasoftware.net).
All DNA samples were positive for albumin detection confirming the good quality of extracted DNA and the possibility to further detect HPV DNA. Among the HNC biopsies, only one oropharyngeal squamous cell carcinoma biopsy sample was positive for HPV-16. The overall HPV prevalence in the HNC biopsy series during the whole study period was 0.74% (95% CI: 0.0-2.2) ( Table 1 To our knowledge, this is the first study on the presence of HPV DNA in head and neck tumors in Central Africa. During a ten years retrospective survey, HPV DNA could be detected in only one out of 135 (less than 1%) biopsy samples from patients suffering from HNC, suggesting that HPV prevalence in HNC in the Central African Republic is very infrequent. In contrast, the majority (65.5%) of cervical cancer biopsy samples collected and analyzed under the same conditions were positive for high-risk HPV.
Our observations appear very different from what has been reported previously in the other regions of the world, where HPV DNA can be detected overall in 26% of HNC [14] . Similar low HPV prevalences in HNC have been previously reported in the AfricanAmerican community in the USA [15] and in Senegal [5] . Taken together, the low HPV prevalence in invasive HNC in Central African Republic suggests that other established risk factors such as alcohol and tobacco consumption as well as eating habits may play a more significant etiological role than HPV infection in HNC in this country. Our findings need to be further validated with supplementary studies that include larger case series and the assessment of region-specific risk factors.
Our study has limitations. The retrospective analysis and the small size of biopsy specimens may have introduced selection bias. In addition, 60.7% of study specimens were HNC from oral cavity or larynx, which are driven more by alcohol and smoking than HPV [4] . Furthermore, HPV prevalence rate in cervical cancer biopsies appear lower than that reported in other studies [16] , suggesting possible low detection sensitivity due to the storage protocol of biopsy samples into paraffin, as mentioned elsewhere [17] . 
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